Abstract: Colon cancer continues to pose a significant worldwide health concern, necessitating effective detection and prompt classification for successful treatment and enhanced patient outcomes.

Early-onset colorectal cancer (EO CRC) is marked by unusually stiff, fibrotic colorectal tissue that actively promotes tumor growth, according to a new study that points to biomechanical remodeling as ...

Claudia Umanita’s stomach pain started slowly in 2024, the kind of dull cramping that could have come from myriad common causes: constipation, her menstrual cycle, a virus. But stomach aches tend to ...

DALLAS — Dr. Bethany Malone has treated a lot of colorectal cancer patients. The youngest, not counting those with genetic conditions, was 19 years old. Colorectal cancer used to be considered a ...

(WSVN) - It’s called the “silent surge” — men in their 30s being diagnosed with colon cancer. 7Investigates why their symptoms are often misdiagnosed. Here’s 7’s Courtney Allen. Thirty-four-year-old ...

Treatment with a GLP-1 receptor agonist (RA) may offer a survival advantage in patients with colon cancer and obesity. In a real-world analysis of nearly 7000 patients with colon cancer, those taking ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." New research links ultra-processed food with a higher colon cancer risk. The risk jumped 1.5 times in ...

Patients with colon cancer using GLP-1 receptor agonists (the class of drugs behind treatments like Ozempic, Wegovy, and Mounjaro) had substantially lower five-year death rates than those not using ...

A new way to screen for colon cancer is giving Americans more options to spot the disease in its early stages. According to the American Cancer Society, 1-in-3 adults do not get screened as ...

GLP-1 drugs such as Ozempic and Wegovy may extend the lives of colon cancer patients, according to a major UC San Diego study. Patients on the medications had less than half the mortality rate of ...

A Scandinavian clinical trial has revealed that low-dose aspirin can halve the risk of colon and rectal cancer recurrence in patients with specific genetic mutations. The research, involving over ...